When Can We Safely Stop Follow-up IPMN Surveillance: Annals of Surgery | July 2026

Introduction:

The widespread detection of intraductal papillary mucinous neoplasms (IPMNs) has substantially increased surveillance programs, although only a small proportion progress to pancreatic cancer. This study evaluated the long-term cancer risk and cost-effectiveness of surveillance to identify patients in whom follow-up can be safely discontinued.

Why was this study needed?

• Incidental IPMN diagnosis is increasing with widespread cross-sectional imaging.
• Most branch-duct IPMNs never progress to pancreatic cancer.
• Current guidelines differ regarding when surveillance can be safely stopped.
• Lifelong surveillance imposes a substantial healthcare and financial burden.
• Evidence-based criteria for surveillance discontinuation are lacking.

Results:

• Only 0.4% of patients developed pancreatic cancer during follow-up, while nearly 30% had stable cysts for at least five years, with a pancreatic cancer risk comparable to the age-matched general population.
• Patients aged ≥75 years with stable cysts for ≥5 years, patients aged ≥65 years with cysts <15 mm stable for ≥5 years, and patients with cysts <10 mm stable for ≥5 years had an extremely low or negligible cancer risk, supporting consideration of surveillance discontinuation.
• Stopping surveillance in these low-risk groups could generate substantial healthcare cost savings without compromising patient safety.

Clinical Impact:

This study supports a risk-adapted surveillance strategy rather than lifelong follow-up for every patient with IPMN. Patients with small, stable branch-duct IPMNs, particularly older individuals, may no longer benefit from continued surveillance once long-term stability has been demonstrated. Clinical decisions should remain individualised, considering patient fitness, life expectancy, and surgical candidacy.

Bottom Line:

Not all IPMNs require lifelong surveillance. Patients with stable, small branch-duct IPMNs—especially those aged ≥75 years or ≥65 years with cysts <15 mm that remain unchanged for five years—may safely discontinue surveillance, potentially reducing unnecessary imaging, patient anxiety, and healthcare costs.